Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer

被引：2
|
作者：
Chiorean, E. Gabriela
Whiting, Scott
Binder, Gary
Dranitsaris, George
Manax, Victoria
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Celgene Corp, Summit, NJ USA
[3] Augmentium Pharma Consulting, Toronto, ON, Canada
[4] Celgene, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [42] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [43] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [44] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [45] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [46] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [47] Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
    Kobayashi, Satoshi
    Suzuki, Motoko
    Ueno, Makoto
    Maruki, Yuta
    Okano, Naohiro
    Todaka, Akiko
    Ozaka, Masato
    Tsuji, Kunihiro
    Shioji, Kazuhiko
    Doi, Keitaro
    Kojima, Yasushi
    Tsumura, Hidetaka
    Tanaka, Kazunari
    Higuchi, Hajime
    Kawabe, Ken
    Imaoka, Hiroshi
    Yamashita, Tatsuya
    Miwa, Haruo
    Nagano, Hiroaki
    Arima, Shiho
    Hayashi, Hideyuki
    Naganuma, Atsushi
    Yamaguchi, Hironori
    Hisano, Terumasa
    Umemoto, Kumiko
    Ishii, Shuji
    Nakashima, Koji
    Suzuki, Rei
    Kitano, Yohei
    Misumi, Toshihiro
    Furuse, Junji
    Ishii, Hiroshi
    ONCOLOGIST, 2022, 27 (10): : E774 - E782
  • [48] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [49] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [50] Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.
    Kim, Sunnie S.
    Signorovitch, James
    Yang, Hongbo
    Patterson-Lomba, Oscar
    Xiang, Cheryl
    Ung, Brian
    Parisi, Monika
    Marshall, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345